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Safety and Efficacy of Hydroxychloroquine in COVID-19: A 
Systematic Review and Meta-Analysis
Waqas Ullaha, i, Hafez M. Abdullahb, Sohaib Roomia, Yasar Sattarc, Talal Almasd, 
 Smitha Narayana Gowdab, Rehan Saeeda, Maryam Mukhtare, Ammar Ahmadf, 
 Tony Oliverb, M. Chadi Alraiesg, Donald C. Haasa, David L. Fischmanh
Abstract
Background: During the initial phases of the coronavirus disease 
2019 (COVID-19) epidemic, there was an unfounded fervor sur-
rounding the use of hydroxychloroquine (HCQ); however, recently, 
the Centers for Disease Control and Prevention (CDC) has recom-
mended against routine use of HCQ outside of study protocols citing 
possible adverse outcomes.
Methods: Multiple databases were searched to identify articles on 
COVID-19. An unadjusted odds ratio (OR) was used to calculate the 
safety and efficacy of HCQ on a random effect model.
Results: Twelve studies comprising 3,912 patients (HCQ 2,512 and 
control 1400) were included. The odds of all-cause mortality (OR: 
2.23, 95% confidence interval (CI): 1.58 - 3.13, P value < 0.00001) 
were significantly higher in patients on HCQ compared to patients 
on control agent. The response to therapy assessed by negative re-
peat polymerase chain reaction (PCR) (OR: 1.83, 95% CI: 0.50 - 
6.75, P = 0.36), radiological resolution (OR: 1.98, 95% CI: 0.47 
- 8.36, P value = 0.36) and the need for invasive mechanical ventila-
tion (IMV) (OR: 1.21, 95% CI: 0.34 - 4.33, P value = 0.76) were 
identical between the two groups. Overall, four times higher odds of 
net adverse events (NAEs) were observed in the HCQ group (OR: 
4.59, 95% CI 1.73 - 12.20, P value = 0.02). The measures for indi-
vidual safety endpoints were also numerically lower in the control 
arm; however, none of these values reached the level of statistical 
significance.
Conclusions: HCQ might offer no benefits in terms of decreasing the 
viral load and radiological improvement in patients with COVID-19. 
HCQ appears to be associated with higher odds of all-cause mortality 
and NAEs.
Keywords: COVID-19; SARS-CoV-2; HCQ; CQ
Introduction
On March 11, 2020, the World Health Organization (WHO) 
officially declared coronavirus disease 2019 (COVID-19) a 
global pandemic. Emerging as a handful of pneumonia case 
clusters in Wuhan, China, in late December 2019, COVID-19 
has now reached all corners of the world. The epicenter of the 
outbreak has shifted over the past 4 months from China to It-
aly and now to New York. As of April 28, 2020, more than 3 
million cases from over 180 countries and more than 200,000 
deaths have been documented worldwide, with the USA ac-
counting for nearly a quarter of all fatalities. The projected 
number of deaths in the USA is between 100,000 and 240,000, 
with an estimated total burden of over 2 million COVID-19 
cases [1].
In response to this extraordinary public health challenge 
and the urgent need for medications to treat this disease, the 
Food and Drug Administration (FDA) established a Coro-
navirus Treatment Acceleration Program (CTAP) and issued 
Emergency Use Authorization (EUA) for chloroquine (CQ) 
and its derivative hydroxychloroquine (HCQ). CQ and HCQ 
(an analog of CQ) are primarily approved for the treatment 
of malaria and chronic inflammatory disorders (rheumatoid 
arthritis), respectively [2]. Scientific literature pertaining to 
the immunopathology of the severe acute respiratory syn-
drome (SARS) and Middle Eastern respiratory syndrome virus 
(MERS) has previously shown some effect of these medica-
tions against those viruses [3]. This lends some credence to 
the use of these medications against severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2). Both drugs are 
thought to prevent the ingress of virions into the host cell, halt 
post-entry cascades and replication of the virus. The former 
is achieved by inhibition of the downstream glycosylation of 
angiotensin-converting enzyme 2 (ACE2) receptors, while en-
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dosomal acidification helps in reducing the overall virus bur-
den [2-4].
Although HCQ was widely adopted for the treatment of 
COVID-19, this appears to have been based on little concrete 
evidence, but rather on anecdotal data emerging from China 
and France. While a few small-scale studies have demonstrat-
ed some favorable outcomes, the safety and efficacy of these 
regimens remain to be proven. This, along with considerable 
concern for HCQ-related adverse outcomes, has prompted us 
to conduct this meta-analysis as we await the results of rand-
omized control trials (RCTs).
Materials and Methods
Search strategy and data extraction
The MEDLINE (PubMed, Ovid), EMBASE, Clinicaltrials.
org and Cochrane databases were queried with various com-
binations of medical subject headings (MeSH) to identify 
relevant articles. There were no language or time restrictions 
placed. Backward snowballing was performed to retrieve un-
identified studies that were missed on the initial search. The 
MeSH used included two subsets: one for the COVID-19 and 
another for HCQ. The two subsets of MeSH were combined 
in a 1:1 combination using Boolean operators. Results from 
all possible combinations were downloaded into an EndNote 
library. All RCTs and observational cohort studies (OCSs) 
until April 30, 2020, were evaluated. Studies comparing 
the safety and efficacy of the HCQ in COVID-19 were in-
cluded. The efficacy endpoints were radiological resolution 
or decreased virological load on repeat polymerase chain re-
action (PCR). Safety outcomes included net adverse events 
(NAEs), a composite of gastrointestinal, respiratory, neuro-
logical and dermatological outcomes. Secondary outcomes 
included components of NAE. Review articles, conference 
papers, and studies with no control arm or insufficient data 
were excluded.
Data analysis
The statistical analysis was performed using the DerSimonian 
and Laird test on a random-effects model to calculate an unad-
justed odds ratio (OR). The probability value of P < 0.05 was 
considered statistically significant. The “test for overall effect” 
was reported as a z-value corroborating the inference from the 
95% confidence interval (CI). If the eligibility of a study was 
dubious or unduly influencing results due to its large sample 
size, a sensitivity analysis was performed. Subgroup analysis 
based on the type of control group (placebo vs. antiviral) was 
also performed. Higgins I-squared (I2) statistical model was 
used to assess variations in outcomes of the included studies. I2 
less than 40% corresponded to low heterogeneity. Depending 
upon the strength of evidence for heterogeneity (P value from 
the Chi-square χ2 analysis), I2 of 41-74% indicated moderate (P 
≥ 0.05) or moderate to severe (P ≤ 0.05), and I2 of 75% or high-
er suggested substantial heterogeneity. Publication bias was il-
lustrated graphically using a funnel plot. The methodological 
quality assessment of the included RCTs was performed using 
the Cochrane collaboration tool for the systematic review and 
meta-analysis, where each study was screened for five differ-
ent types of bias (selection, performance, detection, attrition, 
and reporting bias). All statistical analysis was performed us-
ing the Digitize and the Cochrane Review Manager (RevMan) 
version 5.3.
Quality of the included studies
The overall quality of the included RCTs was high (Fig. 1). 
Due to adequate randomization and allocation concealment, 
the risk of selection bias in RCTs was low. However, three 
retrospective cohort studies introduced a 30% overall risk of 
selection bias. The risks of performance and detection bias 
were high because of inadequate blinding of participants and 
outcomes, respectively. Reporting bias across all studies was 
reduced due to an adequate description of the study results. 
The fact that most RCTs used an intention to treat model or 
had a minimal loss to follow-up of its participants, the risk of 
attrition bias was minimal.
An approval was obtained from the Institutional Review 
Board (IRB).
Results
Search results and study characteristics
The initial search revealed 351 articles. After removal of ir-
relevant and duplicate items, 160 articles were deemed rel-
evant for full-text review. Of these, 148 articles were exclud-
ed based on our selection criteria. Fourteen articles (seven 
RCTs, seven OCSs) qualified for quantitative analysis [5-18]. 
The Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) flow diagram is shown in Figure 
2.
A total of 3,912 patients, 2,512 in HCQ and 1,400 in the 
control arm were included. The mean age was 51 years, com-
prising 65% male patients. Eight studies compared HCQ ther-
apy to standard of care therapy (SCT) on outcomes including 
mortality, viral clearance and radiological resolution. SCT is 
defined as a supportive therapy with no specific treatment for 
COVID-19. The study of Borba et al compared high dose HCQ 
(600 mg twice daily) with low dose HCQ (450 mg twice daily) 
[9]. Huang et al compared HCQ against lopinavir/ritonavir 
therapy [8]. Carlucci et al compared HCQ + azithromycin + 
zinc with HCQ + azithromycin in the control group [14]. The 
baseline characteristics were comparable between the HCQ 
and the control group with a proportion of hypertension (26% 
vs. 21.5%), diabetes mellitus (23% vs. 21%), smoking (23.6% 
vs. 20.5%) and chronic kidney disease (11.7% vs. 13%), re-
spectively. The follow-up period varied from 6 days to 28 days 
with a median follow-up duration being 7 days. The detailed 
account of the inclusion criteria of studies and the baseline 
characteristics of included patients are given in Supplementary 
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Material 1 (www.jocmr.org).
Pooled analysis of efficacy endpoints
A comprehensive pooled analysis of 12 studies did not show 
any benefit with the use of HCQ in any of the efficacy end-
points. Virological clearance assessed by negative repeat PCR 
(OR: 1.83, 95% CI: 0.50 - 6.75, P = 0.36) and radiological 
resolution of concerning findings for COVID-19 (OR: 1.98, 
95% CI: 0.47 - 8.36, P = 0.36) were similar between the two 
groups. The in-hospital requirement for an invasive mechani-
Figure 1. Methodological quality assessment of the included studies.
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cal ventilation (IMV) (OR: 1.21, 95% CI: 0.34 - 4.33, P = 0.76) 
was also identical between patients on HCQ compared to those 
not on HCQ. There was no significant difference between the 
disease progression between the two groups (OR: 2.06, 95% 
CI: 0.26 - 16.40, P = 0.50), while, HCQ was found to be as-
sociated with significantly higher odds of all-cause mortality 
(OR: 2.23, 95% CI: 1.58 - 3.13, P value < 0.00001) compared 
to patients in the control group. The heterogeneity in the out-
comes of the included studies was moderate to high (I2 = 54% 
- 94%) (Figs. 3, 4a).
Pooled analysis of safety endpoints
The incidence of NAE, a composite of all systemic complica-
tions, was used to gauge the safety of HCQ. The NAE with 
HCQ was significantly higher in the HCQ group as compared 
to control groups (OR: 4.59, 95% CI: 1.73 - 12.20, P value = 
0.02) (Fig. 4b). Interestingly, the odds of all individual ad-
verse events were consistently higher but statistically non-
significant in patients receiving HCQ for COVID-19; respira-
tory complications (OR: 1.19, 95% CI: 0.52 - 2.73, P value 
= 0.68), gastrointestinal complications (OR: 1.45, 95% CI: 
0.66 - 3.11, P value = 0.35), neurological adverse symptoms 
(OR: 1.26, 95% CI: 0.20 - 7.98, P value = 0.81), dermatologi-
cal side effects (OR: 3.55, 95% CI: 0.35 - 35.93, P = 0.28), 
cardiac arrest (OR: 0.88, 95% CI: 0.33 - 2.39, P value = 0.81) 
(Fig. 5). In the study of Borba et al [9], a high dose of HCQ 
was associated with a higher rate of QT prolongation, and 
ventricular arrhythmias.
Subgroup sensitivity analysis
Subgroup sensitivity analysis based on the type of medications 
used in combination with HCQ in the experimental group mir-
rored the overall findings of all efficacy endpoints except that 
mechanical ventilation was lower in the study by Carlucci et al 
[14], and control agent was favored in the study by Gautret et 
al [5] in terms of virological seroconversion. The safety profile 
was in concordance with the pooled results for all subgroups 
(Supplementary Materials 2 - 4, www.jocmr.org).
Publication bias
On visual assessment of the funnel plots, publication bias was 
minimal for overall outcomes (Fig. 6). The vertical axis of the 
plot used the standard error to estimate the sample size of the 
study; it is evident that the majority of the included studies fall 
at the bottom, indicating a small sample size. The horizontal 
spread reflected that most studies were underpowered due to a 
wide CI of the effect size.
Discussion
Our meta-analysis of 14 studies comprising 3,816 patients 
Figure 2. PRISMA flow diagram of the included studies in systematic review and meta-analysis. PRISMA: Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses.
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showed no significant difference in the efficacy of HCQ com-
pared to the control arm, while the overall NAEs were five 
times higher in in the former group [5-16]. The individual safe-
ty measures including the incidence of gastrointestinal, res-
piratory, cardiac, dermatological and neurological complica-
tions were numerically higher but statistically non-significant 
between the two groups. Efficacy was gauged by a difference 
in the mortality rate, decrease in the viral load and radiologi-
cal resolution of COVID-19-related findings. While there was 
no significant difference in most of the efficacy endpoints, pa-
tients on HCQ had a two-fold higher rate of in-hospital all-
cause mortality compared to patients on SCT.
Of the included studies, the major efficacy endpoint re-
ferred to the attainment of a negative PCR result, indicating to-
tal viral clearance usually at 5 - 10 days of treatment. A pooled 
analysis of five studies comprising 268 patients revealed that 
a virologic cure was achieved in 84% of patients treated with 
HCQ compared to 77% in the control group. Gautret et al pre-
sented the results of a 14-day trial with 36 patients [5]. This 
was an outlier as the only study that had a statistically signifi-
cant improvement in virologic cure rate. It is unclear if these 
findings could be attributed to the substantial amount of attri-
tion and performance bias seen in this study [5]. Six patients 
on HCQ were prematurely excluded before completion of the 
Figure 3. Forest plot for (a) virological cure, (b) radiological improvement, (c) ventilator required, and (d) progression to severe 
illness showing an individual and pooled OR for studies comparing HCQ-treated patients with control. OR: odds ratio; HCQ: 
hydroxychloroquine.
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study, and there were inconsistencies in the methods and cent-
ers of PCR testing between the two groups. Nevertheless, this 
study triggered massive interest and prompted other research-
ers to further evaluate the efficacy of HCQ. These subsequent 
studies have, however, shown an identical rate of virological 
clearance among both the HCQ-treated and SCT groups, mir-
roring the findings of our pooled analysis. It should be noted 
that the wide CI in our results indicates that it is difficult to draw 
definitive conclusions from the limited data currently available.
Three studies included in our analysis reported resolu-
tion of suggestive radiological findings on computerized to-
mography (CT) as an efficacy outcome [6-8]. A pooled analy-
sis of these studies that comprised 56 (HCT) and 58 patients 
(SCT group) showed a trend favoring resolution in the HCQ 
group (71% vs. 57%), though statistical significance was 
not achieved. Huang et al was the only study that provided a 
breakdown of radiologic features. They reported a higher per-
centage of patients in the control group with the involvement 
of more than two lobes and also bilateral distribution of patchy 
shadows (92% vs. 60% and 91% vs. 60%, respectively) [8].
The most debilitating complication of severe acute res-
piratory syndrome coronavirus 2 (SARS-CoV-2) infection is 
acute respiratory failure necessitating the use of IMV and other 
concurrent resource-intensive needs in critical care units [10]. 
The need for artificial ventilation was reported by four studies, 
comprising 1,357 patients in the HCQ and 919 patients in the 
control group, showing 11% vs. 14% utilization, respectively, 
with a pooled OR of 0.86 [9, 10, 14, 15]. While this favors the 
HCQ group, it was statistically not significant with P value 
of 0.24. Among these four studies, we found that the study 
of Magagnoli et al was not only subject to the bias of non-
randomized data but also to ascertainment issues, i.e., sicker 
patients were more likely to receive HCQ on compassionate 
grounds and hence were more prone to have adverse outcomes 
[10].
Our mortality analysis of 3,004 (HCQ group: 1,907; con-
trol: 1,097) showed a significantly higher rate of all-cause 
mortality in patients in HCQ group compared to those on SCT. 
It should be noted, however, that this difference is principally 
driven by three out of 12 studies with higher population [14-
16]. Magagnoli et al reported a mortality rate three times high-
er in the HCQ group than the SCT group [10]. This finding is 
likely reflective of the inclusion of a sicker population in the 
treatment group, as evidenced by the higher rate of lymphope-
nia and azithromycin use. The study by Borba et al differed in 
terms of its inclusion criteria, comparing a high dose of HCQ 
against a low dose of HCQ [9]. Similarly, Carlucci et al studied 
the efficacy of HCQ, azithromycin, and zinc against HCQ and 
azithromycin, demonstrating increased frequency of discharg-
es (OR: 1.53, 95% CI: 1.12 - 2.09) and low mortality (OR: 
0.449, 95% CI: 0.271 - 0.744) in the zinc regimen arm [14]. 
On the contrary, Rosenberg et al compared SCT with HCQ and 
azithromycin, or HCQ alone, favoring the control arm due to 
a significantly lower need for IMV and mortality [15]. These 
findings were validated by Geleris et al [16]. Overall, the in-
consistencies in the results of the included studies indicate that 
currently there is not enough data available to confirm or refute 
the efficacy of HCQ in this patient population, and we would 
have to wait for further studies to be reported before a more 
accurate assessment can be made [16].
While the therapeutic benefits of HCQ have now been 
widely touted, the adverse effects have not been adequately 
highlighted. In the current context, HCQ is generally thought 
to be safe due to a typically short course of therapy employed 
Figure 4. Forest plot for (a) all-cause mortality, and (b) NAE, showing an individual and pooled OR for studies comparing HCQ-
treated patients with control. NAE: net adverse event; OR: odds ratio; HCQ: hydroxychloroquine.
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for COVID-19. Our overall analysis showed a significantly 
higher incidence of NAEs in patients on HCQ. The individual 
components of the composite were also numerically higher in 
the HCQ arm. On analysis of 1,220 patients, only 29% of the 
SCT group developed adverse reactions compared to 77% of 
patients receiving HCQ. The neurological (1.8% vs. 1.6%), 
respiratory (7.5% vs. 6.5%), cardiac (35% vs. 35%), and gas-
trointestinal (18% vs. 8%) complications were higher in the 
HCQ vs. SCT, respectively. A study by Rosenberg et al report-
ed a higher incidence of cardiac arrest with a combination of 
HCQ and azithromycin (OR: 2.13, 95% CI: 1.12 - 4.05) [15]. 
In light of these trends and with previous studies demonstrat-
ing major side effects of HCQ (cardiomyopathy, QT prolonga-
tion, and retinopathy), a considered risk to benefit determina-
tion should be made prior to HCQ use.
In summary, the available data regarding the effect of HCQ 
on safety and efficacy are limited and fraught with inconsisten-
cies. A better analysis may be possible once more data become 
available from the numerous trials that are currently underway. 
However, it is important to keep in mind that the virologic cure 
Figure 5. Forest plot for (a) respiratory complications, (b) gastrointestinal complications, (c) dermatological side effects, (d) 
neurological complications and (e) cardiac arrest showing an individual and pooled OR for all studies comparing HCQ treated 
patients with control. OR: odds ratio; HCQ: hydroxychloroquine.
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does not necessarily correlate with the resolution of symptoms 
and patient outcomes. At present, our analysis shows that HCQ 
use is not associated with any benefit and could potentially be 
harmful.
Limitations
Our study is constrained by the limitations of the included 
studies. All studies were vastly underpowered due to the small 
sample size. There was significant heterogeneity in the inclu-
sion criteria limiting our ability to perform subgroup analysis. 
Some therapeutic decisions were impacted by the prescriber’s 
discretion, prioritizing treatment of the sicker population, po-
tentially skewing results. Variability in the doses of HCQ, ad-
dition of antiviral agents to control arms, differing PCR test-
ing methods and paucity of major RCTs call for caution while 
interpreting the results of this meta-analysis.
Conclusions
HCQ does not appear to offer significant benefits in terms of 
reducing the viral load, resolution of radiological findings, 
or progression of the COVID-19. HCQ might be associated 
with a higher mortality. Though there are trends in the data, 
pointing towards a higher complication rate with HCQ, greater 
sample size and thus more statistically significant results, are 
needed to better inform the current debate. This meta-analysis 
supports the recommendation that HCQ should not be used 
outside of study protocols.
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